Precision BioSciences (DTIL) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

DTIL Stock Forecast


Precision BioSciences stock forecast is as follows: an average price target of $15.50 (represents a 138.46% upside from DTIL’s last price of $6.50) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

DTIL Price Target


The average price target for Precision BioSciences (DTIL) is $15.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $1.00. This represents a potential 138.46% upside from DTIL's last price of $6.50.

DTIL Analyst Ratings


Buy

According to 3 Wall Street analysts, Precision BioSciences's rating consensus is 'Buy'. The analyst rating breakdown for DTIL stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Precision BioSciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 01, 2024Justin ZelinBTIG--121.24%361.54%
Nov 10, 2022Goldman Sachs---27.54%-84.62%
Row per page
Go to

The latest Precision BioSciences stock forecast, released on Apr 01, 2024 by Justin Zelin from BTIG, set a price target of $30.00, which represents a 121.24% increase from the stock price at the time of the forecast ($13.56), and a 361.54% increase from DTIL last price ($6.50).

Precision BioSciences Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$30.00
Last Closing Price$6.50$6.50$6.50
Upside/Downside-100.00%-100.00%361.54%

In the current month, the average price target of Precision BioSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Precision BioSciences's last price of $6.50. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024BMO CapitalMarket PerformMarket PerformHold
May 16, 2024GuggenheimUnderperformUnderperformHold
May 16, 2024H.C. WainwrightBuyBuyHold
Apr 01, 2024BTIGBuyBuyHold
Jun 17, 2022BMO CapitalOutperformInitialise
Row per page
Go to

Precision BioSciences's last stock rating was published by BMO Capital on Nov 04, 2024. The company gave DTIL a "Market Perform" rating, the same as its previous rate.

Precision BioSciences Financial Forecast


Precision BioSciences Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Revenue---------$13.12M$19.79M$8.78M$10.60M$7.36M$3.82M$3.32M$6.34M$24.04M$68.81M$16.35M$8.85M$7.36M$1.08M$7.00M$6.52M$4.87M$5.39M$5.46M
Avg Forecast$11.00M$11.00M$13.70M$10.00M$3.42M$5.33M$7.70M$5.34M$12.47M$8.99M$6.38M$5.67M$6.81M$9.86M$4.97M$7.73M$9.04M$6.02M$13.86M$8.30M$5.93M$4.34M$5.09M$4.14M$8.74M$6.21M$8.00M$5.55M
High Forecast$12.70M$12.70M$15.82M$11.55M$3.95M$5.36M$7.70M$5.34M$14.40M$9.19M$7.36M$6.55M$7.86M$9.86M$4.97M$7.73M$9.04M$6.02M$13.86M$8.30M$5.93M$4.34M$5.09M$4.14M$8.74M$6.21M$8.00M$5.55M
Low Forecast$9.80M$9.80M$12.21M$8.91M$3.05M$5.31M$7.70M$5.34M$11.11M$8.79M$5.68M$5.06M$6.07M$9.86M$4.97M$7.73M$9.04M$6.02M$13.86M$8.30M$5.93M$4.34M$5.09M$4.14M$8.74M$6.21M$8.00M$5.55M
# Analysts1111211121111111111111111111
Surprise %---------1.46%3.10%1.55%1.56%0.75%0.77%0.43%0.70%3.99%4.96%1.97%1.49%1.69%0.21%1.69%0.75%0.78%0.67%0.98%

Precision BioSciences's average Quarter revenue forecast for Dec 23 based on 2 analysts is $12.47M, with a low forecast of $11.11M, and a high forecast of $14.40M. DTIL's average Quarter revenue forecast represents a -4.96% decrease compared to the company's last Quarter revenue of $13.12M (Sep 23).

Precision BioSciences EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111211121111111111111111111
EBITDA---------$-11.53M$-11.89M$-23.76M$-16.01M$-21.29M$-28.63M$-25.87M$-19.74M$-8.65M$24.34M$-16.22M$-20.98M$-23.52M$-30.25M$-24.45M$-19.11M$-19.34M$-18.27M$-30.66M
Avg Forecast$-8.43M$-8.43M$-10.50M$-7.67M$-2.62M$-4.09M$-5.90M$-4.09M$-9.56M$-6.89M$-4.89M$-4.35M$-5.22M$-7.84M$-3.96M$-29.70M$-7.19M$-4.79M$-11.02M$-21.74M$-4.72M$-3.46M$-4.05M$-24.45M$-6.95M$-4.94M$-6.37M$-85.62M
High Forecast$-7.52M$-7.52M$-9.36M$-6.83M$-2.34M$-4.07M$-5.90M$-4.09M$-8.52M$-6.74M$-4.36M$-3.88M$-4.65M$-7.84M$-3.96M$-23.76M$-7.19M$-4.79M$-11.02M$-17.39M$-4.72M$-3.46M$-4.05M$-19.56M$-6.95M$-4.94M$-6.37M$-68.49M
Low Forecast$-9.74M$-9.74M$-12.13M$-8.85M$-3.03M$-4.11M$-5.90M$-4.09M$-11.04M$-7.05M$-5.64M$-5.02M$-6.02M$-7.84M$-3.96M$-35.64M$-7.19M$-4.79M$-11.02M$-26.09M$-4.72M$-3.46M$-4.05M$-29.34M$-6.95M$-4.94M$-6.37M$-102.74M
Surprise %---------1.67%2.43%5.46%3.07%2.72%7.24%0.87%2.75%1.81%-2.21%0.75%4.45%6.80%7.47%1.00%2.75%3.92%2.87%0.36%

1 analysts predict DTIL's average Quarter EBITDA for Sep 21 to be $-4.79M, with a high of $-4.79M and a low of $-4.79M. This is -119.67% lower than Precision BioSciences's previous annual EBITDA (Jun 21) of $24.34M.

Precision BioSciences Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111211121111111111111111111
Net Income---------$-8.08M$-11.89M$-23.56M$-36.49M$-24.96M$-32.47M$-28.99M$-22.34M$-11.28M$21.66M$-18.69M$-23.45M$-26.02M$-32.70M$-26.84M$-20.92M$-20.74M$-19.44M$-31.78M
Avg Forecast$-1.89M$-2.40M$-510.10K$-2.77M$-16.60M$-15.57M$-15.46M$-17.26M$-14.92M$-39.90M$-53.34M$-49.41M$-44.27M$-70.12M$-91.71M$-32.34M$-99.58M$-124.51M$-93.51M$-25.04M$-105.47M$-138.30M$-124.41M$-26.84M$-103.37M$-105.88M$-80.98M$-88.75M
High Forecast$-1.63M$-2.06M$-437.95K$-2.38M$-14.25M$-13.36M$-13.27M$-14.82M$-12.81M$-34.25M$-45.80M$-42.42M$-38.01M$-70.12M$-91.71M$-25.87M$-99.58M$-124.51M$-93.51M$-20.03M$-105.47M$-138.30M$-124.41M$-21.47M$-103.37M$-105.88M$-80.98M$-71.00M
Low Forecast$-2.28M$-2.89M$-612.69K$-3.33M$-19.94M$-18.70M$-18.57M$-20.73M$-17.92M$-47.92M$-64.07M$-59.34M$-53.17M$-70.12M$-91.71M$-38.81M$-99.58M$-124.51M$-93.51M$-30.05M$-105.47M$-138.30M$-124.41M$-32.20M$-103.37M$-105.88M$-80.98M$-106.50M
Surprise %---------0.20%0.22%0.48%0.82%0.36%0.35%0.90%0.22%0.09%-0.23%0.75%0.22%0.19%0.26%1.00%0.20%0.20%0.24%0.36%

Precision BioSciences's average Quarter net income forecast for Sep 21 is $-124.51M, with a range of $-124.51M to $-124.51M. DTIL's average Quarter net income forecast represents a -674.96% decrease compared to the company's last Quarter net income of $21.66M (Jun 21).

Precision BioSciences SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111211121111111111111111111
SG&A---------$9.63M$9.83M$11.09M$10.07M$10.33M$10.48M$10.69M$10.62M$9.64M$9.94M$9.50M$9.20M$8.53M$8.70M$9.62M$8.48M$7.05M$6.50M$5.00M
Avg Forecast$12.10M$12.10M$15.07M$11.00M$3.76M$5.87M$8.47M$5.87M$13.72M$9.89M$7.01M$6.24M$7.49M$10.67M$5.38M$8.37M$9.79M$6.52M$15.00M$8.99M$6.42M$4.70M$5.51M$4.49M$9.46M$6.72M$8.66M$6.01M
High Forecast$13.97M$13.97M$17.40M$12.70M$4.34M$5.90M$8.47M$5.87M$15.84M$10.11M$8.10M$7.21M$8.64M$10.67M$5.38M$8.37M$9.79M$6.52M$15.00M$8.99M$6.42M$4.70M$5.51M$4.49M$9.46M$6.72M$8.66M$6.01M
Low Forecast$10.78M$10.78M$13.43M$9.80M$3.35M$5.84M$8.47M$5.87M$12.22M$9.67M$6.25M$5.56M$6.67M$10.67M$5.38M$8.37M$9.79M$6.52M$15.00M$8.99M$6.42M$4.70M$5.51M$4.49M$9.46M$6.72M$8.66M$6.01M
Surprise %---------0.97%1.40%1.78%1.35%0.97%1.95%1.28%1.09%1.48%0.66%1.06%1.43%1.81%1.58%2.14%0.90%1.05%0.75%0.83%

Precision BioSciences's average Quarter SG&A projection for Dec 23 is $13.72M, based on 2 Wall Street analysts, with a range of $12.22M to $15.84M. The forecast indicates a 42.38% rise compared to DTIL last annual SG&A of $9.63M (Sep 23).

Precision BioSciences EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111211121111111111111111111
EPS---------$-0.07$-0.00$-0.21$-0.33$-0.23$-0.48$-0.47$-0.37$-0.19$0.38$-0.33$-0.45$-0.50$-0.63$-0.52$-0.41$-0.41$-0.39$-1.99
Avg Forecast$-0.26$-0.33$-0.07$-0.38$-2.28$-2.14$-2.12$-2.37$-2.05$-5.47$-7.32$-6.78$-6.08$-10.00$-13.08$-16.23$-14.20$-17.76$-13.34$-14.90$-15.04$-19.73$-17.74$-15.53$-14.74$-15.10$-11.55$-11.72
High Forecast$-0.22$-0.28$-0.06$-0.33$-1.96$-1.83$-1.82$-2.03$-1.76$-4.70$-6.28$-5.82$-5.22$-10.00$-13.08$-16.23$-14.20$-17.76$-13.34$-14.90$-15.04$-19.73$-17.74$-15.53$-14.74$-15.10$-11.55$-11.72
Low Forecast$-0.31$-0.40$-0.08$-0.46$-2.74$-2.57$-2.55$-2.85$-2.46$-6.58$-8.79$-8.14$-7.30$-10.00$-13.08$-16.23$-14.20$-17.76$-13.34$-14.90$-15.04$-19.73$-17.74$-15.53$-14.74$-15.10$-11.55$-11.72
Surprise %---------0.01%0.00%0.03%0.05%0.02%0.04%0.03%0.03%0.01%-0.03%0.02%0.03%0.03%0.04%0.03%0.03%0.03%0.03%0.17%

According to 1 Wall Street analysts, Precision BioSciences's projected average Quarter EPS for Sep 21 is $-17.76, with a low estimate of $-17.76 and a high estimate of $-17.76. This represents a -4773.16% decrease compared to DTIL previous annual EPS of $0.38 (Jun 21).

Precision BioSciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PASGPassage Bio--1011.11%Buy
XFORX4 Pharmaceuticals--891.89%Buy
BDTXBlack Diamond Therapeutics--507.00%Buy
INZYInozyme Pharma--445.35%Buy
PLRXPliant Therapeutics--209.03%Buy
ABOSAcumen Pharmaceuticals--203.03%Buy
DAWNDay One Biopharmaceuticals--190.85%Buy
STOKStoke Therapeutics--171.52%Buy
TERNTerns Pharmaceuticals--149.56%Buy
DTILPrecision BioSciences--138.46%Buy
MREOMereo BioPharma Group--83.42%Buy
CYTKCytokinetics--74.60%Buy
DYNDyne Therapeutics--47.60%Buy
HOOKHOOKIPA Pharma--30.43%Buy
RVMDRevolution Medicines, Inc. Warrant--6.78%Buy
ALECAlector--6.38%Buy

DTIL Forecast FAQ


Is Precision BioSciences a good buy?

Yes, according to 3 Wall Street analysts, Precision BioSciences (DTIL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of DTIL's total ratings.

What is DTIL's price target?

Precision BioSciences (DTIL) average price target is $15.5 with a range of $1 to $30, implying a 138.46% from its last price of $6.5. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Precision BioSciences stock go up soon?

According to Wall Street analysts' prediction for DTIL stock, the company can go up by 138.46% (from the last price of $6.5 to the average price target of $15.5), up by 361.54% based on the highest stock price target, and down by -84.62% based on the lowest stock price target.

Can Precision BioSciences stock reach $10?

DTIL's average twelve months analyst stock price target of $15.5 supports the claim that Precision BioSciences can reach $10 in the near future.

What are Precision BioSciences's analysts' financial forecasts?

Precision BioSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $21.79M (high $22.35M, low $21.39M), average EBITDA is $-16.705M (high $-16.398M, low $-17.132M), average net income is $-64.89M (high $-55.711M, low $-77.94M), average SG&A $23.97M (high $24.58M, low $23.53M), and average EPS is $-8.905 (high $-7.645, low $-10.695). DTIL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.7M (high $52.77M, low $40.73M), average EBITDA is $-35.034M (high $-31.222M, low $-40.454M), average net income is $-7.579M (high $-6.507M, low $-9.103M), average SG&A $50.27M (high $58.05M, low $44.8M), and average EPS is $-1.04 (high $-0.893, low $-1.249).

Did the DTIL's actual financial results beat the analysts' financial forecasts?

Based on Precision BioSciences's last annual report (Dec 2023), the company's revenue was $48.73M, beating the average analysts forecast of $33.51M by 45.40%. Apple's EBITDA was $-42.527M, beating the average prediction of $-25.691M by 65.53%. The company's net income was $-61.319M, missing the average estimation of $-158M by -61.08%. Apple's SG&A was $39.09M, beating the average forecast of $36.86M by 6.03%. Lastly, the company's EPS was $-0.016, missing the average prediction of $-21.622 by -99.93%. In terms of the last quarterly report (Sep 2023), Precision BioSciences's revenue was $13.12M, beating the average analysts' forecast of $8.99M by 45.88%. The company's EBITDA was $-11.532M, beating the average prediction of $-6.895M by 67.26%. Precision BioSciences's net income was $-8.079M, missing the average estimation of $-39.897M by -79.75%. The company's SG&A was $9.63M, missing the average forecast of $9.89M by -2.63%. Lastly, the company's EPS was $-0.0701, missing the average prediction of $-5.475 by -98.72%